Solid Biosciences Inc. · Brief

Next report

9 days

Nov 9 · after closeest.Q3 FY26

Expected move

No implied move.

6 reportsHistory

1 of 5≥ implied

Aug 11 '22±30.2%▲+3.65%×0.12

Jan 9 '23—▲+2.56%—

Jan 8 '24±15.0%▲+7.59%×0.51

Feb 18 '25±29.3%▲+31.51%×1.07

Q3 FY25±38.3%▼−15.29%×0.40

Q1 FY26±75.6%▲+18.81%×0.25

quarterimplied−80%0+80%realized×

Q1 FY26±75.6%▲+18.81%×0.25

Q3 FY25±38.3%▼−15.29%×0.40

Feb '25±29.3%▲+31.51%×1.07

Jan '24±15.0%▲+7.59%×0.51

Jan '23—▲+2.56%—

Aug '22±30.2%▲+3.65%×0.12

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 9 report · est.

Bull2 of 4

7disclosed supplier and customer ties reported in SEC filingsSEC filings

4tracked funds holding SLDBN-PORT · Aug 31 '26

Bear2 of 4

0.24%of State Street SPDR S&P Biotech ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26

17managers whose positions together make up four fifths of the reported value13F · Jun 30 '26

AI captions · Sep 16 '26once per report · top 2 per case

SLDB report session

No linked exposure.

Oct 26impliedImplied move: ±19.8% into Nov 9 earnings (Oct 26 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.